Atrial Flutter vs. Atrial Fibrillation: Why the Distinction Matters and What to Do About It

A patient walks into clinic with a heart rate stuck at exactly 150 beats per minute. He's been feeling off for three days. Slightly winded going up the stairs. A flutter in the chest he can't quite shake. He thinks it might be anxiety. His EKG comes off the printer and the rhythm tells a story: a rapid, regular ventricular rate of 150, with a sawtooth pattern visible in the inferior leads. This is not anxiety. This is atrial flutter, and it's a rhythm I can usually fix permanently with a one-hour procedure if we play our cards right.

I'm Dr. Damian Rasch, a cardiologist in Encinitas. Atrial flutter and atrial fibrillation get lumped together in patient conversations because they share a lot of features: both involve abnormal atrial rhythms, both raise stroke risk, both can produce palpitations and fatigue, and both often coexist in the same patient. But they are mechanistically different rhythms, they look different on the EKG, and they have meaningfully different treatment options. The most important practical difference is that typical atrial flutter is one of the most curable rhythms in cardiology, whereas atrial fibrillation, while treatable, is rarely truly curable. This article walks through the differences, explains why we treat them differently, and gives you a framework for thinking about your own rhythm if you've been told you have one or both.

What Each Rhythm Is, Mechanically

Atrial fibrillation is what it sounds like: chaos. The atria, instead of contracting in coordinated beats, are quivering. Hundreds of disorganized electrical wavelets are circulating through the atrial muscle, with no single pattern. Most of these wavelets originate from foci near the pulmonary veins (the four veins that drain blood from the lungs into the left atrium), although other triggers exist. The AV node, sitting between the atria and the ventricles, only allows a fraction of these signals through, so the ventricular rate is irregular and often fast. The defining EKG features of AFib are an irregularly irregular rhythm with no discernible P waves.

Atrial flutter is more organized. Instead of chaos, there's a single large reentrant circuit, usually traveling around a fixed anatomic structure in the right atrium called the cavotricuspid isthmus, which is a strip of tissue between the tricuspid valve and the inferior vena cava. The signal goes around this loop at a fast but stable rate, typically 240 to 340 atrial beats per minute. The AV node usually conducts every other beat, producing a ventricular rate near 150. The defining EKG features are a regular ventricular rate (often exactly 150) and the sawtooth flutter waves, most visible in the inferior leads, that mark the continuous atrial activity.

There are two flavors of flutter. Typical flutter, which is the kind I just described, uses the cavotricuspid isthmus. This is the curable one, and it accounts for the majority of clinically encountered flutter. Atypical flutter uses other reentrant circuits, often in the left atrium or in atrial scar from prior surgery or AFib ablation. Atypical flutter is harder to ablate and has a more variable response to treatment, but the principles are similar.

How They Look on the EKG

Once you've seen a few examples, the EKG distinction becomes pattern recognition.

Atrial fibrillation: irregularly irregular rhythm, meaning the spacing between beats is constantly varying with no pattern. No P waves. The baseline between QRS complexes shows fine fibrillatory waves, sometimes hard to see. The ventricular rate is often in the 100s to 130s without rate control, although it can be higher.

Typical atrial flutter: regular ventricular rate, often locked at 150 (because the atrial rate is around 300 and the AV node conducts 2:1). Look at the inferior leads (II, III, aVF). You'll see a continuous sawtooth pattern of negative waves with no isoelectric line between them. The lead V1 sometimes shows the flutter waves as positive deflections. The classic phrase, drilled into every cardiology fellow, is "regular tachycardia at exactly 150 is flutter until proven otherwise."

Atypical flutter: regular tachycardia, but the flutter waves don't follow the classic inferior pattern. They might look upright in the inferior leads, or have unusual morphology, suggesting a non-CTI reentrant circuit. These are usually identified definitively only with electrophysiology study and mapping.

Sometimes patients have both rhythms at once or have one rhythm degenerate into the other. AFib can convert to flutter spontaneously, and flutter can degenerate to AFib. The two rhythms travel together more often than not.

The Symptoms

The symptom profile of flutter and AFib overlap heavily. Patients describe palpitations as a fluttering, racing, or pounding sensation in the chest. Fatigue is common, especially when the rhythm has been ongoing for days. Shortness of breath on exertion is the next most common complaint. Lightheadedness and presyncope can occur, especially when the ventricular rate is very fast or in older patients with stiff hearts. Chest discomfort sometimes accompanies the rhythm, especially in patients with underlying coronary disease, because the fast rate increases myocardial oxygen demand.

The pattern of symptom onset can give clues. AFib often comes on suddenly, lasts hours to days, and resolves either spontaneously or with intervention. Flutter tends to be more sustained, with patients sometimes oblivious to a heart rate of 150 for days. Both rhythms can be entirely asymptomatic, especially in patients who have had them long enough that their heart and body have adapted.

A subset of patients first present with heart failure symptoms from a tachycardia-mediated cardiomyopathy. The heart, beating at 130 or 150 around the clock for weeks or months, develops reduced systolic function. Restoring sinus rhythm or controlling the rate carefully usually allows the cardiomyopathy to recover, but it takes time and identification of the underlying rhythm matters.

Why Both Cause Strokes

The stroke risk in both rhythms comes from the same mechanism: stagnant blood in the left atrium, especially in the left atrial appendage, can clot. When sinus rhythm returns or even sometimes during the rhythm itself, that clot can dislodge and travel to the brain, producing a stroke.

For AFib, the stroke risk is well-quantified. The CHA2DS2-VASc score (which counts congestive heart failure, hypertension, age, diabetes, prior stroke, vascular disease, and female sex) gives a risk estimate. Patients with a score of 2 or higher (men) or 3 or higher (women) get anticoagulation, usually with a direct oral anticoagulant like apixaban, rivaroxaban, dabigatran, or edoxaban.

Atrial flutter was historically thought to carry a lower stroke risk than AFib, but multiple studies over the last two decades have shown the risk is similar enough that we apply the same anticoagulation rules. A patient with flutter and a CHA2DS2-VASc score of 2 or higher gets anticoagulated. The reasoning is partly that flutter and AFib coexist in the same patients more often than not, so even if pure flutter carries a slightly lower risk, the practical risk is comparable.

Anticoagulation is one of those decisions where the math is clear once you know the score. For a patient with hypertension, diabetes, and age over 65, the annual stroke risk without anticoagulation is in the range of 4 to 6 percent. With a DOAC, that risk drops to around 1 percent. The major bleeding risk on a DOAC is roughly 1 to 2 percent per year. The net benefit is substantial for most patients, although the calculation is individualized when bleeding risk is high (recurrent GI bleeding, recent intracranial hemorrhage, certain occupational risks).

Why Flutter Is the More Curable Rhythm

Here's where the distinction between flutter and AFib stops being academic and becomes practical.

Typical atrial flutter, which uses the cavotricuspid isthmus, can be cured with a single ablation procedure with a success rate of around 95 percent. The procedure takes about an hour, the ablation catheter places a line of lesions across the cavotricuspid isthmus, and the reentry circuit is interrupted. The flutter goes away and stays away. Recurrence rates are low (5 to 10 percent over years), and most recurrences are not flutter again but rather development of AFib in patients who were already on the AFib spectrum.

By contrast, AFib ablation, which usually involves pulmonary vein isolation with an ablation catheter or a cryoballoon, is a longer and more complex procedure. Success rates are around 70 to 80 percent for paroxysmal AFib at one year, dropping to 50 to 60 percent for persistent AFib. Many patients need more than one ablation to maintain sinus rhythm. The procedure itself takes two to four hours, and the recovery is longer. Pulse field ablation, a newer technology, has improved both safety and efficacy somewhat, but AFib ablation is still a meaningfully bigger undertaking than flutter ablation.

For patients with both rhythms, the strategy often involves treating both. If a patient has a clear flutter substrate, ablating the flutter first eliminates that source of symptoms and stroke risk and lets us see what AFib burden remains. Some patients who had both end up with substantial reductions in AFib after flutter ablation, suggesting that flutter was driving or triggering some of the AFib episodes.

Atypical flutter is a different story. Because the reentrant circuit isn't anchored to the cavotricuspid isthmus, ablating it requires careful electrophysiologic mapping during the procedure to find and target the specific circuit. Success rates are lower than typical flutter, often in the 70 to 85 percent range, and the procedure takes longer. Atypical flutter often arises after AFib ablation, when scar from the prior procedure creates new reentrant circuits, and these patients often need multiple procedures to fully manage their arrhythmia.

The Treatment Options for Each Rhythm

Atrial Fibrillation

Treatment of AFib has three components: anticoagulation, rate or rhythm control, and risk factor modification.

Anticoagulation, as discussed above, is based on stroke risk. DOACs are first-line for most patients. Warfarin is still used in patients with mechanical valves or moderate-to-severe mitral stenosis.

Rate control aims for a resting ventricular rate below 110 in most patients, sometimes lower in symptomatic patients. Beta-blockers (metoprolol, atenolol, carvedilol) and non-dihydropyridine calcium channel blockers (diltiazem, verapamil) are the main agents. Digoxin is occasionally used as a second agent, especially in patients with heart failure.

Rhythm control aims for sinus rhythm. Options include cardioversion (electrical or chemical), antiarrhythmic medications (flecainide, propafenone for patients without structural disease; amiodarone, dofetilide, sotalol for those with structural disease), and catheter ablation. Recent trials, including EAST-AFNET 4, suggest that early rhythm control improves outcomes compared to rate control alone in many patients, especially those with recently diagnosed AFib.

Risk factor modification is increasingly recognized as a major piece of long-term AFib management. Weight loss, blood pressure control, sleep apnea treatment, alcohol moderation, and exercise capacity all influence AFib burden. The LEGACY and CARDIO-FIT studies showed that aggressive lifestyle interventions can reduce AFib recurrence substantially, sometimes by half.

Atrial Flutter

Treatment of flutter overlaps with AFib but with one major addition: ablation, especially for typical flutter, is so effective and safe that I push for it earlier in the course of management than I would for AFib.

Acute management of flutter often involves rate control with a beta-blocker or calcium channel blocker, then either cardioversion or ablation depending on the situation. If the patient has had flutter for less than 48 hours and is anticoagulated, cardioversion can be done relatively safely. If the duration is longer or anticoagulation status is uncertain, a transesophageal echocardiogram is sometimes done first to rule out a left atrial appendage clot before cardioversion.

For patients with documented typical flutter, I usually have a conversation about ablation early, often as soon as the diagnosis is confirmed. The procedure is short, the recovery is quick, the success rate is high, and the upside (no medications, no recurrent rhythm, often improved energy) is substantial. Patients who decline ablation can be managed with anticoagulation and rate control or with antiarrhythmic medications, but the long-term outlook is better with ablation in most cases.

For atypical flutter, the conversation is more nuanced. The procedure is more complex, the success rate is lower, and the substrate is often part of a larger left atrial scar pattern that includes AFib. Decisions are made in coordination with electrophysiology specialists who do these procedures regularly.

Anticoagulation rules for flutter mirror those for AFib. CHA2DS2-VASc score guides the decision. After successful ablation with sustained sinus rhythm, the question of whether to continue anticoagulation indefinitely depends on the underlying stroke risk profile and on whether AFib has been documented or is likely to develop, which it does in a meaningful fraction of post-flutter-ablation patients.

When the Two Travel Together

Many patients have both rhythms, either at different times or sometimes in alternation. The clinical implications depend on the pattern.

Some patients have flutter as the dominant rhythm, with occasional brief AFib. Ablating the flutter often improves their overall arrhythmia burden meaningfully, although a residual AFib pattern usually persists. These patients are good candidates for flutter ablation as the first-line procedure.

Other patients have AFib as the dominant rhythm, with occasional flutter, often after attempted rhythm control with antiarrhythmic medications. The flutter can be a side effect of the medication (especially flecainide or propafenone, which can convert AFib into a slow flutter that conducts 1:1 and produces dangerous ventricular rates). These patients usually benefit from ablating both rhythms, sometimes in a combined procedure.

A third group develops atypical flutter after AFib ablation, where scar from the AFib ablation creates new reentrant circuits. These patients often need a follow-up procedure to map and ablate the new flutter circuit.

The big picture is that flutter and AFib are best thought of as two manifestations of the same atrial substrate disease. Patients with one are at elevated risk for the other. Long-term management often involves an evolving plan that addresses both rhythms over time.

When to Escalate Care

Call 911 immediately for chest pain, severe shortness of breath, syncope, or any combination of those during a known or suspected fast rhythm. The fast ventricular rates of flutter or AFib with rapid conduction can produce ischemia in patients with coronary disease, and the threshold for intervention is appropriately low.

Contact your cardiologist or arrhythmia team the same day if you develop sustained palpitations that don't resolve, new shortness of breath at rest or with mild activity, presyncope, or any concern that the rhythm has changed. Many practices have an arrhythmia nurse line that can triage these calls and arrange same-day evaluation.

Schedule a clinic visit within one to two weeks for new-onset palpitations that come and go, mild fatigue you suspect might be rhythm-related, or for follow-up after a known rhythm event. Patients with smartwatches that detect AFib or rapid heart rates can bring those tracings to the visit, which often shapes management.

Common Patient Questions

My Apple Watch says I have AFib. Should I be alarmed?

Take it seriously, but don't panic. Smartwatches are reasonably good at detecting irregular rhythms, although they are not perfect and they don't distinguish reliably between AFib, flutter, and certain other rhythms. The right next step is a 12-lead EKG, ideally during a symptomatic episode, to confirm the rhythm. If the rhythm is confirmed as AFib or flutter, the workup proceeds as outlined above. If the watch detection turns out to be a false positive (which happens), no further intervention is needed beyond reassurance. The watch readings are useful clues, not diagnoses, and they're best handled in partnership with a cardiologist who can put them in context.

Why is my heart rate stuck at 150?

A heart rate locked at exactly 150 in an adult is one of the most reliable clinical signs of typical atrial flutter with 2:1 conduction. The atrial rate is around 300, the AV node only conducts every other beat, and the resulting ventricular rate is 150. If your heart rate has been stuck at 150 for hours or days, get an EKG. Flutter can be entirely asymptomatic in some patients, but the rhythm should still be addressed because the long-term consequences of sustained 150 beats per minute include tachycardia-mediated cardiomyopathy and elevated stroke risk. The good news, if it does turn out to be flutter, is that the treatment options are excellent.

If I have flutter, do I really need anticoagulation?

In most cases, yes. The historic teaching that flutter carries lower stroke risk than AFib has not held up in modern data. We treat them the same way, using CHA2DS2-VASc to determine whether anticoagulation is indicated. If you have a CHA2DS2-VASc score of 2 or higher (or 3 if you're female), anticoagulation is recommended, regardless of whether your rhythm is flutter, AFib, or both. After a successful flutter ablation with documented sustained sinus rhythm, the question of stopping anticoagulation can be revisited, but the decision usually depends on whether you also have AFib and on your underlying stroke risk profile.

How long does flutter ablation take?

A typical cavotricuspid isthmus ablation for typical flutter takes about one hour of procedure time. Total time in the cath lab, including preparation and recovery, is usually three to four hours. Patients often go home the same day. The success rate for typical flutter ablation is around 95 percent, with low complication rates. Most patients return to normal activities within a few days. Compared to AFib ablation, flutter ablation is one of the most efficient and effective procedures in cardiology.

What's the chance my flutter comes back after ablation?

Flutter recurrence after a successful cavotricuspid isthmus ablation is in the 5 to 10 percent range over five years. What's more common is the development of new AFib after flutter ablation, which happens in about 30 percent of patients within five years, depending on the underlying atrial substrate. Patients who develop AFib after a successful flutter ablation are managed with the standard AFib pathway, sometimes including a separate AFib ablation. The flutter ablation itself stays effective even when AFib develops; the two rhythms are mechanically distinct.

Can flutter cause heart failure?

Yes. Sustained tachycardia from any cause, including flutter, can produce a tachycardia-mediated cardiomyopathy. The heart, beating at 150 around the clock for weeks to months, develops reduced systolic function. Patients can present with shortness of breath, leg swelling, and fatigue, with an echocardiogram showing reduced ejection fraction. The good news is that this cardiomyopathy is reversible in most cases when the rhythm is converted or controlled. Recovery takes weeks to months, and the heart can return to normal function. The lesson is that prolonged uncontrolled flutter or AFib should be addressed, even in patients without obvious symptoms, because the silent damage can be substantial.

What lifestyle changes help?

For both flutter and AFib, the lifestyle interventions overlap. Weight loss in patients with elevated BMI has been shown to reduce AFib burden substantially. Aggressive blood pressure control reduces the atrial substrate that supports both rhythms. Sleep apnea treatment with CPAP reduces nighttime AFib episodes and probably reduces flutter as well. Alcohol moderation matters; even one or two drinks a night can trigger AFib in susceptible patients. Regular aerobic exercise improves cardiovascular health overall and is associated with reduced arrhythmia burden when not overdone (extreme endurance training can paradoxically increase AFib risk). Caffeine in moderate amounts is usually fine for most patients.

My doctor mentioned the Watchman device. What's that about?

The Watchman is a left atrial appendage closure device, used in patients with AFib (and sometimes flutter) who can't tolerate long-term anticoagulation because of bleeding risk. It's placed via catheter and seals off the left atrial appendage, which is the source of most AFib-related blood clots. After it's placed and tissue grows over it, anticoagulation can usually be discontinued. The Watchman doesn't treat the rhythm; it just removes the stroke source. It's an option for patients who are stuck choosing between unacceptable bleeding risk on anticoagulation and unacceptable stroke risk off anticoagulation. I have a separate article on the Watchman device on the site if you want more detail.

A Final Note From Me

The most important thing about flutter, in my view, is that it's one of the few common rhythms in cardiology that we can usually cure outright. Patients sometimes spend years on antiarrhythmic medications and rate-controlling agents for a rhythm that an electrophysiologist could ablate in an hour with a 95 percent success rate. The mismatch between treatment effort and treatment efficacy is striking. If you've been told you have typical atrial flutter, please have a serious conversation with your cardiologist about ablation as a first-line option, not as a last resort.

For AFib, the picture is more complex. Ablation is meaningfully effective, but no AFib ablation is a guaranteed cure, and the long-term plan often involves a combination of rhythm control, rate control, anticoagulation, and lifestyle modification. The good news is that AFib is one of the most actively researched arrhythmias in cardiology, and the treatment landscape has improved dramatically over the last fifteen years. Patients diagnosed today have options that didn't exist a decade ago.

Both rhythms benefit from anticoagulation in patients at appropriate stroke risk, both benefit from underlying risk factor modification, and both deserve a thoughtful conversation between patient and clinician about goals and options. The patients I worry about are the ones who never quite understood which rhythm they had or what the options were. The patients I'm hopeful about are the ones who got a clear diagnosis, a clear plan, and an active partnership in managing their care over time.

References

1. January, Craig T., L. Samuel Wann, Hugh Calkins, et al. "2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation." Journal of the American College of Cardiology 74, no. 1 (2019): 104-132.

2. Hindricks, Gerhard, Tatjana Potpara, Nikolaos Dagres, et al. "2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation." European Heart Journal 42, no. 5 (2021): 373-498.

3. Kirchhof, Paulus, A. John Camm, Andreas Goette, et al. "Early Rhythm-Control Therapy in Patients with Atrial Fibrillation." New England Journal of Medicine 383, no. 14 (2020): 1305-1316.

4. Page, Richard L., Jose A. Joglar, Mary A. Caldwell, et al. "2015 ACC/AHA/HRS Guideline for the Management of Adult Patients with Supraventricular Tachycardia." Circulation 133, no. 14 (2016): e506-e574.

5. Calkins, Hugh, Gerhard Hindricks, Riccardo Cappato, et al. "2017 HRS/EHRA/ECAS/APHRS/SOLAECE Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation." Heart Rhythm 14, no. 10 (2017): e275-e444.

6. Da Costa, Antoine, Patrick Thiercelin, Pierre Antoine Romeyer-Bouchard, et al. "Long-Term Outcomes after Catheter Ablation of Cavo-Tricuspid Isthmus-Dependent Atrial Flutter." Circulation: Arrhythmia and Electrophysiology 13, no. 8 (2020): e008502.

7. Reddy, Vivek Y., Andrea Natale, Stylianos Tzeis, et al. "Pulsed Field or Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation." New England Journal of Medicine 389, no. 18 (2023): 1660-1671.

8. Pathak, Rajeev K., Megan E. Middeldorp, Melissa Meredith, et al. "Long-Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort: The LEGACY Study." Journal of the American College of Cardiology 65, no. 20 (2015): 2159-2169.

9. Pathak, Rajeev K., Adrian D. Elliott, Megan E. Middeldorp, et al. "Impact of Cardiorespiratory Fitness on Arrhythmia Recurrence in Obese Individuals with Atrial Fibrillation." Journal of the American College of Cardiology 66, no. 9 (2015): 985-996.

10. Holmes, David R., Saibal Kar, Matthew J. Price, et al. "Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients with Atrial Fibrillation versus Long-Term Warfarin Therapy." Journal of the American College of Cardiology 64, no. 1 (2014): 1-12.

Published on damianrasch.com. The above information was composed by Dr. Damian Rasch, drawing on individual insight and bolstered by digital research and writing assistance. The information is for educational purposes only and does not constitute medical advice.